Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. by Zinnall, Ulrike et al.
Accepted Manuscript
Micropapillary urothelial carcinoma: evaluation of HER2 status
and immunohistochemical characterization of the molecular
subtype
Ulrike Zinnall, Veronika Weyerer, Eva Compérat, Philippe
Camparo, Nadine T. Gaisa, Ruth Knuechel-Clarke, Aurel Perren,
Alessandro Lugli, Marieta Toma, Gustavo Baretton, Glen
Kristiansen, Ralf M. Wirtz, Liang Cheng, Bernd Wullich, Robert
Stoehr, Arndt Hartmann, Simone Bertz
PII: S0046-8177(18)30190-4
DOI: doi:10.1016/j.humpath.2018.05.022
Reference: YHUPA 4587
To appear in: Human Pathology
Received date: 23 March 2018
Revised date: 11 May 2018
Accepted date: 15 May 2018
Please cite this article as: Ulrike Zinnall, Veronika Weyerer, Eva Compérat, Philippe
Camparo, Nadine T. Gaisa, Ruth Knuechel-Clarke, Aurel Perren, Alessandro Lugli,
Marieta Toma, Gustavo Baretton, Glen Kristiansen, Ralf M. Wirtz, Liang Cheng, Bernd
Wullich, Robert Stoehr, Arndt Hartmann, Simone Bertz , Micropapillary urothelial
carcinoma: evaluation of HER2 status and immunohistochemical characterization of the
molecular subtype. Yhupa (2018), doi:10.1016/j.humpath.2018.05.022
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Micropapillary urothelial carcinoma: evaluation of HER2 status and 
immunohistochemical characterization of the molecular subtype 
 
Ulrike Zinnall a,b*, Veronika Weyerer a*#, Eva Compérat MD c, Philippe Camparo MD d, Nadine 
T. Gaisa MD/ PhD e, Ruth Knuechel-Clarke MD e, Aurel Perren MD f, Alessandro Lugli MD f, 
Marieta Toma MD g,1, Gustavo Baretton MD g, Glen Kristiansen MD h, Ralf M. Wirtz PhD i, 
Liang Cheng MD j, Bernd Wullich MD k, Robert Stoehr PhD a, Arndt Hartmann MD a, Simone 
Bertz MD a  
 
a Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University 
Erlangen-Nürnberg, 91054 Erlangen, Germany. 
b Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute 
for Medical Systems Biology, 13125 Berlin, Germany 
c Department of Pathology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, UPMC 
Paris VI, 75020 Paris, France. 
d Centre de Pathologie Amiens Picardie, 80000 Amiens, France.  
e Institute of Pathology, RWTH Aachen University, 52074 Aachen, Germany.  
f Institute of Pathology, University of Bern, 3008 Bern, Switzerland. 
g Institute of Pathology, University Hospital Carl Gustav Carus, 01307 Dresden, Germany. 
h Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany. 
i STRATIFYER Molecular Pathology GmbH, 50935 Cologne and Institute of Pathology at The 
St Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany. 
j Department of Pathology and Laboratory Medicine and Urology, Indiana University School 
of Medicine, Indianapolis, IN 46202, USA. 
k Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-
Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany. 
* These authors contributed equally to this work. 
# Corresponding author. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Present address: 
1 Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany. 
 
 
Contact information: Veronika Weyerer, Institute of Pathology, University Hospital 
Erlangen, Friedrich Alexander University Erlangen-Nürnberg, Krankenhausstr. 8-10, D-91054 
Erlangen, Germany, Email: veronika.weyerer@uk-erlangen.de, Phone: +49-9131-85 25675, 
Fax: +49-9131-85 25674.  
 
Running title: Micropapillary urothelial carcinoma: HER2 status and molecular subtype 
Conflict of interest: The authors declare no conflict of interests. 
Funding: This research did not receive any specific grant from funding agencies in the 
public, commercial, or not-for-profit sectors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Abstract 
 
Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct 
subtypes with potential therapeutic implications. In this study, we focused on micropapillary 
urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart 
from genetic alterations shared with conventional UBC alterations of the HER2 gene have 
been reported in higher frequencies. However, only small cohorts of MPUCs have been 
analyzed and the real impact is still unclear. We collected a cohort of 94 MPUCs and 
immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, 
FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, 
HER2 amplification status was assigned by chromogenic in-situ-hybridization. Sanger 
sequencing of Exon 4 and 8 was used to test for HER2 mutations. Kruskal-Wallis test was 
calculated to compare marker distribution between proportions of the MPUC component. 
2+/3+ HER2 staining scores were identified in 39.6% of 91 analyzed MPUCs and were not 
differentially distributed among the proportion of the MPUC component (p=0.89). 
Additionally, CISH analysis revealed 30% of HER2 amplified tumors independently of the 
MPUC fraction. In 6/90 evaluable MPUCs a p.S310F HER2 mutation was detected. 
Overexpression of luminal markers was observed in the majority of MPUC. Our 
investigations of the largest cohort of analyzed MPUC demonstrate that HER2 
overexpression and amplifications are common genetic alterations and identification of 
overexpressed luminal markers allows sub-classification to the luminal subtype. These 
findings highlight the need of histomorphological recognition of MPUC and analysis of HER2 
status and the luminal molecular subtype for potential targeted therapeutic strategies.  
 
Keywords: urothelial bladder cancer; micropapillary variant; HER2; molecular subtype; 
targeted therapy. 
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1. Introduction 
 
Urothelial bladder cancer (UBC) is the fifth most common malignancy worldwide in men and 
one of the most cost-consuming cancers as a result of financial expenses not only for 
therapy but also for life time follow-up examination. In the recent years and due to the lack of 
therapeutic advances and targeted therapies, comprehensive molecular characterization 
studies put a lot of effort and insight into the genomic landscape of UBC and provided 
several potential targets. Moreover, whole-genome mRNA expression profiling studies 
proposed distinct molecular categories of UBC similar to the breast cancer classification and 
defined different prognostic groups and appropriate therapeutic options [1]. 
 
In this study, we focus on micropapillary urothelial carcinomas (MPUC), a rare subtype first 
reported by Amin et al. in 1994,  accounting for 0.7-6% of all UBC [2]. According to 
micropapillary carcinomas in other organs such as lung or breast, MPUC is 
histomorphologically characterized by several small-sized nests of tumor cells within lacunar 
spaces which may or may not have a central vascular core located [3]. Clinical and 
prognostic comparison between MPUC and conventional UBC showed a poorer prognosis 
for this distinct variant, probably due to a more aggressive behavior with frequent lymphatic 
invasion resulting in a higher rate of metastases [4, 5]. 
 
Besides these differences in the clinical behavior, very limited data exist about the molecular 
background of this specific subtype. Interestingly, by testing the Human epidermal growth 
factor receptor 2 (HER2) gene amplification among UBC, mutated tumors presented more 
often with specific features such as micropapillary morphology [6]. HER2 is a receptor 
tyrosine-protein kinase and a member of the epidermal growth factor receptor family. 
Activation of the receptor through dimerization and autophosphorylation initiates several 
signaling pathways including cell proliferation. In breast cancer, amplification or 
overexpression of HER2 are known to be responsible for the development of aggressive 
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subtypes and the use of anti-HER2 antibodies combined with standard chemotherapy is well 
established and a prime example for an applied targeted therapy [7]. Concerning the 
possible association of MPUC and HER2 status, several studies identified a higher rate of 
HER2 amplification, mutations and/ or overexpression compared to the detected numbers in 
conventional urothelial tumors [8-11]. However, due to the low incidence rates of MPUC the 
available reports are conducted in low sample sized cohorts (below 60 cases). Therefore, the 
real impact of a potential target among this histomorphological subgroup remains unclear.    
 
The aim of our study was to collect the largest cohort of MPUC to date and to validate the 
expression, mutation and amplification status of the HER2 gene as a possible therapeutic 
strategy among MPUC tumors. Moreover, with regard to the recently identified molecular 
categories of UBC we used basal and luminal immunohistochemical markers to assign 
MPUC to a specific subgroup.  
 
2. Materials and methods 
 
2.1 Study cohort 
In total, 94 archival formalin-fixed, paraffin-embedded MPUC of the urinary bladder were 
collected from several cooperation partners and from the files of the Institute of Pathology of 
the Friedrich-Alexander-University Erlangen-Nürnberg. Complete histomorphological 
reevaluation of at least one hematoxylin and eosin (H&E)-stained tumor slide according to 
the current WHO classification system was performed by two experienced uropathologists 
(A. H., S. B.)  Reevaluation included assessment of the percentage of the micropapillary 
component in tumors with mixed morphology [3]. All cases presented the classical 
appearance of invasive micropapillary carcinomas and were included if at least 15% of the 
tumor showed clear micropapillary differentiation. Table 1 represents the clinico-pathological 
characteristics of the analyzed MPUC cohort. Prior institutional review board (University 
Hospital Erlangen) approval was obtained for molecular analysis on archival material. 
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Representative pictures of the micropapillary histomorphological features are shown in 
Figure 1.  
 
2.2 Immunohistochemistry analysis 
A tissue microarray (TMA) was constructed containing cores specifically punched from 
marked micropapillary regions of 94 MPUCs. Immunohistochemistry was performed on TMA 
slides including only the variant component using a Ventana Bench Mark Ultra automatic 
stainer. All antibodies used by this method are listed in Table 2. Single markers were chosen 
to classify the MPUC cohort: CK5, CD44, p63 und EGFR for defining the basal and CD24, 
CK20, GATA3 and FOXA1 for the luminal subtype. Manual staining was performed for 
FOXA1 (polyclonal, 1:1000; Abcam, ab23738). CD24 immunohistochemistry was performed 
automatically (Dilution 1:5; SWA-11; Ventana Medical Systems, Inc.; Tucson, USA) by our 
cooperation partners at the Institute of Pathology, University Hospital Bonn, Germany. HER2 
immunohistochemistry was evaluated according to the recommendations of the American 
Society of Clinical Oncology and the College of American Pathologists [12]. All other 
immunohistochemical markers were analyzed according to the immunoreactive score (IRS) 
by Remmele and Stegner resulting from multiplication of percentage score (0=0, 1=<10%, 
2=10-50%, 3=51-80%, 4=>80%) and intensity score (assessment of the staining intensity of 
positive cells: 0=negative, 1=weak, 2=intermediate, 3=strong). IRS=0 was considered 
negative, IRS 1-5 weakly positive and IRS 6-12 strongly positive [13].  
 
2.3 HER2-Chromogenic in situ hybridization (CISH) 
CISH analysis was performed on TMA slides using the SPEC HER2/CEN 17 Probe Kit 
(Zytovision) following the manufacturer’s instructions. Scoring was performed according to 
the revised ASCO/CAP guidelines for HER2 amplification in breast cancer [12]. 
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2.4 Microdissection and DNA isolation  
According to marked H&E-stained sections of the evaluated tumors manual microdissection 
of the micropapillary component and DNA isolation was performed as described previously 
[14]. For DNA isolation the Maxwell 16 LEV Blood DNA Kit (Promega, Mannheim, Germany) 
was used according to the manufacturer´s instructions and included only the variant 
component.  
 
2.5 HER2 exon 4 and exon 8 mutation analysis  
Exon 4 and 8 of the HER2 gene were amplified by PCR (used primers: for Exon 4: sense: 5´-
CAG AAG GTG ACA GAA GGG-3´; antisense: 5´-CTG TCT GAG AGA AGA GGG-3´ and for 
Exon 8: sense: 5´-TCA TGG TGG TGC ACG AAG, antisense: 5´-AAC TGC AGC TGG CCT 
CGG-3´) (Metabion, Martinsried, Germany) in a total volume of 25µl containing 
approximately 100ng DNA, 0.2mM dNTP, 0.18µM primers and 0.025U/µl GoTaq (Promega, 
Mannheim, Germany). Thermal cycling conditions: initial denaturation for 3 min at 94°C, 45 
cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, elongation at 72°C for 
1 min, final primer extension at 72°C for 10 min. Gradient PCR was used for optimization of 
cycling conditions. PCR-products (size: Exon 4: 226bp, Exon 8: 211bp) were purified using 
the Qiagen Dye Ex 2.0 TM Spin Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions. Sanger Sequencing analysis was performed with PCR primers 
using Applied Biosystems Big Dye Terminator v1.1 Cycle Sequencing Kit and an Applied 
Biosystems ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, USA). 
 
2.6 Statistical analysis 
Kruskal-Wallis test was used to assess differences between the proportion of the MPUC 
components and were calculated using R, version 3.2.3. The heatmap.2 function of the 
gplots package within the R 3.2.3 statistical environment was used for non-hierarchical 
clustering based on immunoreactive scores of the evaluated markers. 
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3. Results  
 
3.1 HER2 protein expression and amplification 
In total, 91/94 (96.8%) MPUC cases were evaluable for HER2 immunohistochemistry. Figure 
2 shows representative images of the scoring. 36/91 (39.6%) tested MPUC demonstrated a 
HER2 score of 2+ and 3+ (Table 3). Comparing tumors with different proportions of the 
MPUC component we observed no differences in the distribution of HER2 protein 
overexpression rate (p=0.89). CISH analysis was evaluable in 70 out of 94 tumors. 
Representative images are displayed in Figure 2. HER2 amplification was found in 21/70 
(30.0%) MPUC. HER2 amplified tumors were independently distributed among MPUC, 
regardless of the proportion of the MPUC component (p=0.61, Table 3). Correlation of 
amplification status with a high protein expression showed 16/21 (76.2%) HER2 amplified 
MPUCs with a HER2 protein expression score of 2+ or 3+, in 5 amplified cases protein 
expression was weak (score 1+) or absent (Table 4).  
 
3.2 HER2 mutation analysis 
The HER2 mutation status of exon 4 and 8 was analyzed in 90 available MPUC samples. 
Sequencing data of both exons were available for 89/90 (98.7%) tumors (Table 5). The only 
alteration identified was a p.S310F mutation in 6/90 (6.7%) MPUCs located within exon 8 
(Figure 3A). In one case results were only available for exon 8 and presented wildtype HER2 
sequence. Furthermore, we detected four MPUCs showing the minor T allele of the single 
nucleotide polymorphism (SNP) rs56114611 located within exon 4 (Figure 3B). Moreover, 
the combination of sequencing and CISH data revealed two HER2 p.S310F mutated MPUCs 
with concomitant HER2 amplification and three cases with a 2+/3+ HER2 scoring.  
 
3.3 Immunohistochemical analysis of basal and luminal markers 
90/94 MPUC with immunohistochemical results were included in the heat map analysis. Non-
hierarchical clustering determined similarity of the used luminal and basal markers. Figure 4 
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illustrates the combination and expression levels of the different markers. Strong expression 
of luminal markers was found in the vast majority of cases, with a weak and strong 
expression of CD24 in 93.1%, CK20 in 76.9%, GATA3 86.8% and FOXA1 in 85.2%. In 
contrast, basal markers were predominantly not expressed. With regard to the distinct 
percentages of the MPUC component, we did not identify a differential distribution of the 
luminal or basal markers (Table 6).  
 
4. Discussion 
 
MPUC is associated with aggressive behavior and poor survival most probably due to 
frequent lymphatic invasion and metastases [5, 15]. In comparison with MPUC of the upper 
urinary tract both malignancies present with similar aggressive characteristics [16]. Adverse 
outcomes despite aggressive platinum-based chemotherapy and limited response to 
Bacillus-Calmette-Guerin instillation therapy have been reported in MPUC, but little is known 
about alternative treatment strategies and most authors recommend early aggressive 
surgical treatment [5]. Recently, our own studies on MPUC showed worse outcome 
compared to conventional UBC after transurethral resection and radiochemotherapy [17]. In 
another study it has been shown that any amount of the MPUC variant is significant and 
should be reported [18]. Moreover, the biological scenario of the variant is largely unknown: a 
recent study reported that TERT mutations identified in UBC were also frequently observed 
among MPUC [19]. Improvement of our knowledge about this morphological variant and 
search for new therapy strategies are urgently needed. 
 
Among breast cancer patients HER2 IHC analysis is used to identify patients suitable for 
anti-HER2 targeted therapies [7]. In conventional UBC, HER2 overexpression frequencies 
have been reported ranging from 9.2 to 71% [20-22].  In the largest series of 1005 invasive 
UBC only 9.2% presented a positive (Score 2+ to 3+) HER2 staining [22]. Recently, due to 
the need of a guided exploration Moktefi et al. reported, that HER2 evaluation in UBC should 
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include immunohistochemistry as screening step adding FISH testing if needed. Additionally, 
MPUC in this study presented with a higher proportion of HER2 positive tumors [23]. In 
concordance with this the few available small sample sized MPUC cohorts reported higher 
numbers of HER2 positive tumors: Schneider and colleagues found 30/61 (50%) positive (2+ 
and 3+) MPUC cases [10]. Another study detected an increased HER2 protein expression in 
13/19 (68%) MPUC [11]. Moreover, an overexpression rate of 74% of 27 investigated MPUC 
tumors has been shown. However, more than half of these positive cases were scored 2+ 
according to the ASCO scoring system [24]. Recently, Behzatoglu et al. showed a 3+ 
staining in 34 of 60 MPUC [9]. In our own study, a 2+/3+ HER2 staining was found in 38.3% 
of evaluable MPUC. The variability of IHC results among conventional or MPUC studies may 
be due to the cohort size as well as methodical differences. Despite standardized evaluation 
recommendations, assessment of IHC suffers from high interobserver variability depending 
on training of the pathologist [25]. In our department, HER2 immunohistochemical assay is 
validated in annual round-robin tests and protocols are certified according to ISO 17020. 
Furthermore, evaluation of this study was performed by two experienced pathologists. Due to 
this high standardization and the large number of evaluated MPUC we summarize, that 
HER2 overexpression is particularly seen among MPUC.  
 
Tschui et al. aimed to better characterize HER2 amplified UBC and observed micropapillary 
morphology as a hallmark of these mutated tumors [6]. During the last years, several studies 
reported HER2 amplifications in MPUC cohorts with variable frequencies of 15 to 42% [10, 
26]. We found HER2 amplifications in 21 of 70 investigated MPUCs via CISH analysis. The 
high variability of reported frequencies may be due to the relatively small cohorts investigated 
in most studies. Additionally, the diversity may result from differences in methodology, i.e. 
CISH or FISH, and analysis of TMA spots or whole tumor sections. Due to the high number 
of MPUC investigated in our study, the frequency of 30% HER2 amplifications, which lies in 
between the reported values, seems to be a realistic estimation of the actual percentage. In 
comparison to reported amplifications rates of 5.1-10% in unselected cohorts of UBC, HER2 
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amplified tumors seem to be remarkably more frequent among the micropapillary variant [22, 
27, 28]. Since our CISH analyses were performed on TMA slides, cases with heterogeneous 
distribution of HER2 amplifications may have been missed [22]. Summarized, almost one 
third of MPUC showed an HER2 amplification opening a promising therapy option for this 
rare subtype for example as a complementary therapeutic element in a neoadjuvant setting 
[29]. 
 
Another point of interest is the absence of HER2 protein expression (score 0 or 1+) in 24% of 
HER2 amplified MPUCs. This finding is in line with different studies showing a considerable 
discrepancy between results of immunoreactive score and amplification status. By using 
FISH analysis Caner et al. observed in 3 out of 16 overexpressed tumors a HER2 
amplification among UBC [27]. In addition, heterogeneous pattern between amplified cases 
and mRNA/protein expression were identified among the TCGA cohort. The analysis of 
different “omics” levels in the TCGA cohort revealed, that amplified tumors with low 
expression levels tended to have increased gene methylation pointing to an important impact 
for epigenetic regulation and a complex landscape [29]. 
 
Using next generation sequencing (NGS) analysis Ross et al. found HER2 mutations 
(p.S310F/Y, p.R157W) in 6/15 tested MPUC, whereas HER2 protein overexpression and 
amplification was not detected [8]. In our study 6.7% of evaluable MPUCs revealed p.S310F 
mutation and none of the other reported ones. P.S310Y/F alterations are probably activating 
mutations which have also been detected in other cancer entities and are considered to be 
sensitive to HER2 inhibitors [30]. The high discordance may be due to the very few samples 
used in the NGS study as well as threshold values set for evaluation of NGS results. Notably, 
there is no information whether these findings were validated by a second sequencing 
method [8]. Since we did not perform NGS based analysis we may have missed some 
mutations. However, a similar rate of 7% HER2 mutations was identified among the TCGA 
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cohort [31]. Our results suggest that somatic HER2 mutations do not seem to play a 
dominant role among MPUC patients.  
 
Several comprehensive characterization studies based on mRNA expression profiling 
proposed molecular classification systems of UBC into prognostic significant distinct 
subtypes, whereby transfer of mRNA-based subtyping to immunohistochemical marker 
profiles is currently being discussed [1, 32]. A consensus paper summarized high CK5/14 
and low levels of FOXA1/GATA3 as the characterizing markers of the basal type [33]. CD44, 
p63 and EGFR were previously identified and used as basal markers [1]. CK20 and CD24 
are predominately represented among luminal tumors [1, 34]. In our study, by using a limited 
and selected immunohistochemical panel we detected a strong expression of the luminal 
markers CD24, FOXA1, GATA3 and CK20, whereas basal markers (CD44, CK5, EGFR, 
p63) were predominantly not expressed, assuming that MPUC represent the luminal subtype 
of UBC. Our results are in line with previous findings of the study by Guo et al. identifying the 
luminal character based on whole mRNA and immunohistochemical analyses of CD44, 
CK14, GATA3 and UPK2 in a cohort of 43 MPUC samples [35]. Additionally, HER2 
amplification and overexpression were significantly more often identified in tumors with 
luminal characteristics and therefore operate in the context of the luminal pathway [29]. This 
co-occurrence of HER2 amplified and overexpressed samples among luminal tumors is in 
line with our findings among MPUC cases evolving through the luminal molecular pathway.  
 
 
5. Conclusions 
 
To the best of our knowledge, this is the largest cohort of MPUC to date being 
comprehensively evaluated for HER2 status by using immunohistochemistry, CISH and 
mutational analysis. Additionally, we were able to assign MPUC to the luminal molecular 
subtype using TMA based immunohistochemical analysis. Our findings and the size of our 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
cohort may better reflect the actual frequency of overexpressed and/or amplified tumors 
compared to available low size studies. Given the relatively high frequency of HER2 
overexpression and/or amplification in almost one third of MPUC, our study demonstrates the 
importance of recognition of this histomorphological variant and its potential therapeutic 
impact. However, HER2 mutations do not seem to play a major role in MPUC due to their low 
frequency. Summarized, routine implementation of HER2 immunohistochemistry at least 
and/or assessment of HER2 amplification status to improve therapeutic strategies of this 
aggressive subtype should be considered.  
 
 
Acknowledgments 
We thank Rudolf Jung, Verena Popp, Stefanie Herlein, Claudia Giedl and Christa 
Winkelmann for their excellent technical support. Parts of this study were presented at the 
annual meeting of the German Association of Pathology; May, 2015; Berlin, Germany. We 
acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-
Universität Erlangen-Nürnberg (FAU) within the funding programme Open Access 
Publishing.  
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
References 
 
1. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into 
pathogenesis and clinical diversity. Nat Rev Cancer 2015; 15: 25-41. 
2. Amin MB, Ro JY, el-Sharkawy T et al. Micropapillary variant of transitional cell 
carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous 
carcinoma. Am J Surg Pathol 1994; 18: 1224-1232. 
3. Moch H, Cubilla AL, Humphrey PA et al. The 2016 WHO Classification of Tumours of 
the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. 
Eur Urol 2016; 70: 93-105. 
4. Lopez-Beltran A, Montironi R, Blanca A, Cheng L. Invasive micropapillary urothelial 
carcinoma of the bladder. Hum Pathol 2010; 41: 1159-1164. 
5. Willis DL, Flaig TW, Hansel DE et al. Micropapillary bladder cancer: current treatment 
patterns and review of the literature. Urol Oncol 2014; 32: 826-832. 
6. Tschui J, Vassella E, Bandi N et al. Morphological and molecular characteristics of 
HER2 amplified urothelial bladder cancer. Virchows Arch 2015; 466: 703-710. 
7. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: 
Overexpression and Therapeutic Implications. Mol Biol Int 2014; 2014: 852748. 
8. Ross JS, Wang K, Gay LM et al. A high frequency of activating extracellular domain 
ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 2014; 20: 
68-75. 
9. Behzatoglu K, Yorukoglu K, Demir H, Bal N. Human Epidermal Growth Factor 
Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma. Eur 
Urol Focus 2016. 
10. Schneider SA, Sukov WR, Frank I et al. Outcome of patients with micropapillary 
urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies 
patients with poor outcome. Mod Pathol 2014; 27: 758-764. 
11. Ching CB, Amin MB, Tubbs RR et al. HER2 gene amplification occurs frequently in 
the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. 
Mod Pathol 2011; 24: 1111-1119. 
12. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal 
growth factor receptor 2 testing in breast cancer: American Society of Clinical 
Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 
2013; 31: 3997-4013. 
13. Remmele W, Stegner HE. [Recommendation for uniform definition of an 
immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) 
in breast cancer tissue]. Pathologe 1987; 8: 138-140. 
14. Stoehr R, Zietz S, Burger M et al. Deletions of chromosomes 9 and 8p in 
histologically normal urothelium of patients with bladder cancer. Eur Urol 2005; 47: 58-63. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
15. Jackson BL, Mohammed A, Mayer N et al. Is Immediate Radical Cystectomy 
Necessary for All Patients with Non-Muscle-Invasive Micropapillary Bladder Cancer? Urol Int 
2016; 96: 32-38. 
16. Guo CC, Tamboli P, Czerniak B. Micropapillary variant of urothelial carcinoma in the 
upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med 2009; 133: 
62-66. 
17. Bertz S, Wach S, Taubert H et al. Micropapillary morphology is an indicator of poor 
prognosis in patients with urothelial carcinoma treated with transurethral resection and 
radiochemotherapy. Virchows Arch 2016; 469: 339-344. 
18. Comperat E, Roupret M, Yaxley J et al. Micropapillary urothelial carcinoma of the 
urinary bladder: a clinicopathological analysis of 72 cases. Pathology 2010; 42: 650-654. 
19. Nguyen D, Taheri D, Springer S et al. High prevalence of TERT promoter mutations 
in micropapillary urothelial carcinoma. Virchows Arch 2016; 469: 427-434. 
20. Jimenez RE, Hussain M, Bianco FJ, Jr. et al. Her-2/neu overexpression in muscle-
invasive urothelial carcinoma of the bladder: prognostic significance and comparative 
analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-2447. 
21. Gandour-Edwards R, Lara PN, Jr., Folkins AK et al. Does HER2/neu expression 
provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002; 
95: 1009-1015. 
22. Lae M, Couturier J, Oudard S et al. Assessing HER2 gene amplification as a potential 
target for therapy in invasive urothelial bladder cancer with a standardized methodology: 
results in 1005 patients. Ann Oncol 2010; 21: 815-819. 
23. Moktefi A, Pouessel D, Liu J et al. Reappraisal of HER2 status in the spectrum of 
advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Mod Pathol 
2018. 
24. Goodman AL, Osunkoya AO. Human epidermal growth factor receptor 2 expression 
in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases. Hum Pathol 
2016; 57: 160-164. 
25. Layfield LJ, Frazier S, Esebua M, Schmidt RL. Interobserver reproducibility for 
HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest and 
the 4B5 antibody clone. Pathol Res Pract 2016; 212: 190-195. 
26. Figueroa JD, Ye Y, Siddiq A et al. Genome-wide association study identifies multiple 
loci associated with bladder cancer risk. Hum Mol Genet 2014; 23: 1387-1398. 
27. Caner V, Turk NS, Duzcan F et al. No strong association between HER-2/neu protein 
overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol 
Oncol Res 2008; 14: 261-266. 
28. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in 
urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of 
cases. Am J Clin Pathol 2008; 130: 274-281. 
29. Kiss B, Wyatt AW, Douglas J et al. Her2 alterations in muscle-invasive bladder 
cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep 2017; 7: 
42713. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
30. Herter-Sprie GS, Greulich H, Wong KK. Activating Mutations in ERBB2 and Their 
Impact on Diagnostics and Treatment. Front Oncol 2013; 3: 86. 
31. Cancer Genome Atlas Research N. Comprehensive molecular characterization of 
urothelial bladder carcinoma. Nature 2014; 507: 315-322. 
32. Robertson AG, Kim J, Al-Ahmadie H et al. Comprehensive Molecular 
Characterization of Muscle-Invasive Bladder Cancer. Cell 2017; 171: 540-556 e525. 
33. Lerner SP, McConkey DJ, Hoadley KA et al. Bladder Cancer Molecular Taxonomy: 
Summary from a Consensus Meeting. Bladder Cancer 2016; 2: 37-47. 
34. Choi W, Porten S, Kim S et al. Identification of distinct basal and luminal subtypes of 
muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer 
Cell 2014; 25: 152-165. 
35. Guo CC, Dadhania V, Zhang L et al. Gene Expression Profile of the Clinically 
Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol 2016; 70: 611-620. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Figure legend 
 
Figure 1: A-D Histomorphological spectrum of MPUC (H&E-stained, 200x magnification).  A, 
B: Typical slender papillary proliferations with peritumoral clefts mimicking lymphovascular 
invasion. C: Several micropapillae may be seen within a single lacuna. D: Cytoplasmic 
vacuoles forming ring-like structures are also characteristic features of MPUC. 
 
Figure 2: A, B: Representative pictures of HER2 immunohistochemistry (400x 
magnification). A: HER2 immunoscore 2+. B: HER2 immunoscore 3+; C, D: Sample images 
of HER2 amplification (630x magnification). C: Tumor with a high-level HER2 amplification.  
D: Aneuploid tumor with 6 or more HER2 signals in the majority of tumor cells.  
 
Figure 3: A: Sanger sequencing of exon 8 shows a p.S310F mutation. B: Sanger 
sequencing of exon 4 shows the SNP rs56114611.  
 
Figure 4: Heatmap presenting immunohistochemistry results for luminal and basal markers. 
Each column represents 1 TMA spot; cases with <3 basal and luminal markers were 
excluded, white fields represent not available TMA-spots; red fields represent high 
immunoreactive scores (IRS), green fields represent low IRS. 
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Table 1. Study characteristics of the analyzed cohort 
 MPUC cohort 
n (%) 
Total number of cases 94 
Age distribution, yr  
    Minimum/ maximum 41-99 
    Median age 68 
    Not available 6 
Gender  
    Male 61 (81.3) 
    Female 14 (18.7) 
    Not available 19 
Stage distribution  
    pT1 7 (8.6) 
    pT2 24 (29.6) 
    pT3 29 (35.8) 
    pT4 21 (25.9) 
    Unknown 13 
Grading WHO 2016  
    Low-grade 0 
    High-grade 94 (100.0) 
Grading WHO 1973  
    G1 0 
    G2 9 (9.6) 
    G3  85 (90.4) 
Proportion of the MPUC component  
    15-70% 24 (25.5) 
    80-90% 17 (18.1) 
    95-100% 53 (56.4) 
MPUC: Micropapillary urothelial carcinoma, WHO: Word Health 
Organization 
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Table 2. Antibodies used for immunohistochemistry on a Bench Mark Ultra automatic stainer 
(Ventana).  
Antibody Company Clone Dilution, 1: 
CD44 Dako DF1485 40 
CK20 Dako Ks20.8 50 
CK5 Zytomed XM26 50 
EGFR Novocastra EGFR25 50 
GATA3 DCS L50-823 ready to use 
HER2 Dako Poly 1000 
p63 DCS SFI-6 100 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 3. HER2 protein overexpression and amplification rates among the MPUC cohort. 
 
 
 
  
 MPUC 
cohort 
 Proportion of the MPUC 
component n (%) 
Comparison 
 
 n (%)  15-70% 80-95% 100% p-value 
Total number of cases 94  24 17 53  
HER2 protein expression       
    0 23 (25.3)  6 (26.1) 3 (18.8) 14 (26.9) p=0.89  
    1+ 32 (35.2)  7 (30.4) 6 (37.5) 19 (36.5)  
    2+ 23 (25.3)  9 (39.1) 5 (31.2) 9 (17.3)  
    3+ 13 (14.3)  1 (4.3) 2 (12.5) 10 (19.2)  
    Not available 3  1 1 1  
HER2 amplification status       
    Non-amplified 49 (70.0)  13 (68.4) 9 (81.8) 27 (67.5) p=0.61 
    Amplified 21 (30.0)  6 (31.6) 2 (18.2) 13 (32.5)  
    Not available 24  5 6 13  
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Table 4. HER2 immunohistochemistry in combination with HER2 CISH results. 
     MPUC 
cohort 
n (%) 
 HER2 protein expression 
n (%) 
     0 1+ 2+ 3+ Not available 
Total number of cases 94  23 32 23 13 3 
HER2 amplification status        
    Non-amplified 49 (70.0)  13 (92.9) 22 (84.6) 10 (52.6) 4 (36.4) 0 
    Amplified 21 (30.0)  1 (7.1) 4 (15.4) 9 (47.4) 7 (63.6) 0 
    Not available 24  9 6 4 2 3 
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Table 5. Molecular analysis of exon 4 and 8 of the HER2 gene. 
 
  
 MPUC 
cohort 
 Proportion of the MPUC 
 component n (%) 
 n (%)  15-70% 80-95% 100% 
Total number of cases 94  24 17 53 
HER2 exon 4+8 analyzed samples      
    Wildtype 84 (93.3)  23 (100.0) 14 (82.4) 47 (94.0) 
        Partly evaluable* 1  0 1 0 
    Mutated 6 (6.7)  0 3 (17.6) 3 (6.0) 
    Not available 4  1 0 3 
*Only exon 8 was analyzed and presented with wildtype sequence. 
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Table 6. Basal and luminal markers among the MPUC cohort 
 MPUC 
cohort 
 Proportion of the MPUC component 
n (%) 
Comparison 
 n (%)  15-70% 80-95% 100% p-value 
Total number of cases 94  24 17 53  
Basal markers       
    CD44       
        Negative 80 (92.0)  20 (90.9) 14 (93.3) 46 (92.0) p=0.81 
        Weak 7 (8.0)  2 (9.1) 1 (6.7) 4 (8.0)  
        Strong 0   0 0 0  
        Not available 7  2 2 3  
    CK5       
        Negative 78 (87.6)  17 (81.0) 14 (87.5) 47 (90.4) p=0.90 
        Weak 9 (10.1)  3 (14.2) 2 (12.5) 4 (7.7)  
        Strong 2 (2.2)  1 (4.8) 0 1 (1.9)  
        Not available 5  3 1 1  
    p63       
        Negative 69 (82.1)  17 (77.3) 13 (86.7) 39 (83.0) p=0.35 
        Weak 8 (9.5)  3 (13.6) 1 (6.7) 4 (8.5)  
        Strong 7 (8.3)  2 (9.1) 1 (6.7) 4 (8.5)  
        Not available 10  2 2 6  
    EGFR       
        Negative 53 (58.9)  12 (52.2) 10 (66.7) 31 (59.6) p=0.55 
        Weak 31 (34.4)  10 (43.5) 4 (26.7) 17 (32.7)  
        Strong 6 (6.7)  1 (4.3) 1 (6.7) 4 (7.7)  
        Not available 4  1 2 1  
Luminal markers       
    CK20       
        Negative 21 (23.1)  2 (8.3) 5 (31.2) 14 (27.5) p=0.60 
        Weak 9 (9.9)  1 (4.2) 2 (12.5) 6 (11.7)  
        Strong 61 (67.0)  21 (87.5) 9 (56.3) 31 (60.8)  
        Not available 3  0 1 2  
    GATA3       
        Negative 12 (13.2)  1 (4.4) 2 (12.5) 9 (17.3) p=0.59 
        Weak 31 (34.1)  7 (30.4) 6 (37.5) 18 (34.6)  
        Strong 48 (52.7)  15 (65.2) 8 (50.0) 25 (48.1)  
        Not available 3  1 1 1  
     FOXA1       
        Negative 13 (14.8)  3 (13.0) 3 (21.4) 7 (13.7) p=0.97 
        Weak 17 (19.3)  2 (8.7) 2 (14.3) 13 (25.5)  
        Strong 58 (65.9)  18 (78.3) 9 (64.3) 31 (60.8)  
        Not available 6  1 3 2  
    CD24       
        Negative 6 (6.9)  0 0  6 (11.8) p=0.96 
        Weak 21 (24.1)  6 (28.6) 4 (26.7) 11 (21.5)  
        Strong 60 (69.0)  15 (71.4) 11 (73.3) 34 (66.7)  
        Not available 7  3 2 2  
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Micropapillary urothelial carcinoma: evaluation of HER2 status and 
immunohistochemical characterization of the molecular subtype 
 
Highlights 
 
 Evaluation of 94 invasive, rare micropapillary urothelial carcinomas (MPUC) 
 
 Comprehensive characterization of HER2 by using IHC, CISH and mutation analysis 
 
 Almost one third of amplified and/or overexpressed HER2 tumors 
 
 Molecular classification of MPUC into the luminal subtype by using IHC markers 
 
 Need of histomorphological recognition to test for HER2 and to improve therapy 
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